Testing lisaftoclax for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, lisaftoclax (APG-2575), for people with certain slow-growing B-cell lymphomas. It's for those who haven't had treatment or can't take standard targeted therapy, or who had a targeted therapy but it didn't work well or caused serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of slow-growing B-cell lymphoma (CLL, WM, or MZL).
- You either haven't been treated before and can't take a standard targeted therapy (called a BTK inhibitor) because of other health issues, or you've had only one BTK inhibitor as your first treatment and it didn't work or you had to stop it due to side effects.
- Your blood counts are sufficient (hemoglobin ≥ 70, neutrophils ≥ 0.5, and platelets ≥ 50, or ≥ 30 if lymphoma is in your bone marrow).
- Your liver and kidneys work well enough (certain lab tests are within limits).
- You haven't taken any other BCL-2 inhibitor drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial tests a combination of two targeted drugs for people with mantle cell lymphoma that has come back or stopped responding after prior treatment with a BTK inhibitor. The goal is to see if this new combination can effectively shrink tumors.
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
Hear when a new Indolent Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.